|Day Low/High||37.14 / 37.47|
|52 Wk Low/High||37.59 / 67.34|
Loss of bank leadership and the recent pullback are major factors in what's ailing the markets, says Jim Cramer.
The EpiPen-maker has received a letter from the FDA about its manufacturing facility in Nashik, India.
Washington needs to do more, Gottlieb says at his confirmation hearing.
The maker of the EpiPen seems incapable of overcoming its troubles.
The company's shares were falling again on Wednesday, this time on the news that its initial application for an anti-asthma generic had been rejected by the FDA.
The S&P 500 inches higher in mixed trading Wednesday as a rally in crude helps the energy sector.
The company could be gearing up for multiple challenges on the D.C. front, analysts say.
The company hired Paul Bisaro, former chairman at Allergan, to become CEO as Morgan Stanley helps explore alternatives, including a sale.
With a 100-plus-year history, generous dividend, and diversified portfolio, could this Big Pharma player be resistant to Trump's drug price twitterstorm?
Investors weren't completely distracted by the Affordable Care Act debate.
Mylan CEO Heather Bresch's father sponsored a bill that made it easier for generic drugs to be substituted back in 1986. This helped Mylan become the largest generic manufacturer.
- TLE400 is a fixed-combination containing Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg -
The settlement provides Mylan with global licenses for its trastuzumab product.
A firestorm in Washington has created a fire sale for shares of this undervalued stock.
Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.
Jim Cramer ponders the bull market and whether the drug rally is 'Trumped up.'
The scandals plaguing the pharmaceutical company can be traced to lack of change at the board level.
Is this small-cap biotech play the best way to profit from the growing worldwide demand for vaccines?